Editor’s Note: As of May 7, 2025 Minaris Regenerative Medicine became Minaris Advanced Therapies. The announcement below reflects the name of our organization at the time of publication.
Allendale, NJ, USA and Taipei, Taiwan – October 2, 2024
Minaris Regenerative Medicine, LLC (Minaris) and TFBS Bioscience Inc. (TFBS) are pleased to announce a strategic partnership in cell and gene therapy (CGT) in North America. This collaboration is designed to enhance their capabilities to drive industry innovation by providing one-stop-shop solutions.
The strategic partnership between Minaris and TFBS leverages their complementary strengths across different regions to optimize the CGT supply chain. By integrating TFBS’s expertise in viral vector technologies and Minaris’ capability in cell therapy manufacturing, the collaboration spans from R&D to GMP production for advanced therapies, including CAR-T, CAR-NK, and TCR-T. This alliance aims to provide a one-stop-shop solution in the key North American and European markets, supporting the growth of the CGT industry, integrating services in compliance to international guidelines, while expanding market reach by joint marketing efforts.
“We are thrilled to partner with TFBS in this strategic collaboration,” said Dr. Hiroto Bando, Chief Executive Officer of Minaris. “This alliance is a testament to our commitment to advancing the field of cell and gene therapy by combining our expertise in cell therapy manufacturing with TFBS’s cutting-edge viral vector technologies. Together, we are positioned to drive significant advancements, particularly for the companies in Taiwan seeking to enter the North American market, and to enhance our ability to deliver transformative therapies to patients across North America.”
“Our collaboration with Minaris represents a significant step forward in strengthening the cell and gene therapy ecosystem in North America.” said Tatung Yuan, Chairman and Chief Executive Officer of TFBS. “With our GMP commercial viral vector facility launched in Taiwan by the end of 2024, we are enthusiastic about the potential of this partnership to create new opportunities for both companies and the industry.”
This partnership reflects a shared commitment to advancing the field of cell and gene therapy and is expected to significantly contribute to the development of innovative therapeutic solutions. For more information, please contact:
About TFBS Bioscience Inc.
TFBS Bioscience Inc. (TFBS) was founded in 2016 as the first contract research organization providing biological testing in Taiwan after its spin-off from Development Center for Biotechnology, a government-sponsored research institute. TFBS has established strong track records in several regulatory submissions, winning trust from the international regulatory agencies and biopharmaceutical industry. TFBS has launched the first viral vector contract development and manufacturing facility in Taiwan, providing fully integrated end-to-end contract development and manufacturing services for the needs of clinical trials. TFBS offers manufacturing expertise in adeno-associated virus, lentivirus, and retrovirus. With the customization specialty and state-of-the-art facility, TFBS is the best partner offering clients a one-stop-shop solution for gene and cell therapy. For more information, please visit www.tfbsbio.com.
Contact: Shao-Hua Lo
Director, Business Development
TFBS Bioscience Inc.
E-Mail: shlo@tfbsbio.com
Phone: +886-2-2694788